Pacer BioThreat Strategy ETF (VIRS)
| Assets | $4.00M |
| Expense Ratio | 0.70% |
| PE Ratio | 28.73 |
| Shares Out | n/a |
| Dividend (ttm) | $0.33 |
| Dividend Yield | 0.83% |
| Ex-Dividend Date | Sep 26, 2024 |
| Payout Ratio | 23.94% |
| 1-Year Return | +34.34% |
| Volume | 1,985 |
| Open | 40.03 |
| Previous Close | 40.02 |
| Day's Range | 40.00 - 40.03 |
| 52-Week Low | 30.30 |
| 52-Week High | 40.03 |
| Beta | n/a |
| Holdings | 3 |
| Inception Date | Jun 24, 2020 |
About VIRS
The Pacer BioThreat Strategy ETF (VIRS) is an exchange-traded fund that is based on the LifeSci BioThreat Strategy index. The fund tracks a market-cap weighted index of US companies whose products or services address biological threats to human health. VIRS was launched on Jun 24, 2020 and is issued by Pacer.
Dividends
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Sep 26, 2024 | $0.0723 | Oct 2, 2024 |
| Jun 27, 2024 | $0.1042 | Jul 3, 2024 |
| Mar 21, 2024 | $0.07697 | Mar 27, 2024 |
| Dec 27, 2023 | $0.08002 | Jan 3, 2024 |
| Sep 21, 2023 | $0.07853 | Sep 27, 2023 |
| Jun 22, 2023 | $0.09238 | Jun 28, 2023 |
News
Pacer Advisors, Inc. to Close and Liquidate the Pacer BioThreat Strategy ETF (VIRS) and the Pacer CSOP FTSE China A50 ETF (AFTY)
MALVERN, Pa.--(BUSINESS WIRE)--Pacer Advisors, Inc. to Close and Liquidate the Pacer BioThreat Strategy ETF (VIRS) and the Pacer CSOP FTSE China A50 ETF (AFTY).
Biotech Innovations Remain At Forefront
The first quarter of 2021 was challenging for the biotechnology industry, as the selloff in March represented a sharp reversal from record highs in February. While the sector has remained relatively r...
Healthcare: A Wide Choice Of Large And Well-Established Companies
The advantage for dividend investors in this sector is the wide choice of large and well-established companies. AbbVie is a drug company with strong exposure to the immunology and the oncology markets...
These are the ETFs with the most exposure to the year's best-performing stock
Semiconductor behemoth Nvidia Corp. is the biggest gainer in the S&P 500 for the year to date, up 127%, heftily ahead of second-place West Pharmaceuticals Inc. , which has only gained 87%. The exchang...
Beating COVID-19 With The Pacer BioThreat Strategy ETF (Podcast Transcript)
Beating COVID-19 With The Pacer BioThreat Strategy ETF (Podcast Transcript)
Beating COVID-19 With The Pacer BioThreat Strategy ETF (Podcast)
Rushed to market just 6 months into the COVID-19 pandemic, the Pacer BioThreat Strategy ETF (VIRS) takes a unique approach to picking potential pandemic winners.
3 ETFs For Nvidia's Big Arm Holdings Acquisition
News broke Saturday that semiconductor giant Nvidia (NASDAQ: NVDA) is in talks to acquire Arm Holdings, a UK-based chip designer, from Japan's SoftBank Group for $40 billion.
VIRS Makes Pandemic, Vaccine ETF Competition More Interesting
It was just a week ago that the first exchange-traded fund dedicated to vaccine developers, plenty engaged in the fight against the coronavirus, came to market.